Comparative Pharmacology
Head-to-head clinical analysis: PERIACTIN versus TAVIST 1.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PERIACTIN versus TAVIST 1.
PERIACTIN vs TAVIST-1
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cyproheptadine is a first-generation antihistamine with anticholinergic and antiserotonergic properties. It acts as a competitive antagonist at histamine H1 receptors and serotonin 5-HT2 receptors, thereby inhibiting histamine-mediated allergic symptoms and serotonin-mediated effects such as increased gastrointestinal motility and vascular permeability.
TAVIST-1 (clemastine fumarate) is a first-generation antihistamine that acts as a competitive antagonist at histamine H1 receptors, thereby preventing histamine-mediated effects such as vasodilation, increased capillary permeability, and bronchoconstriction. It also exhibits anticholinergic and sedative properties.
4 mg orally three times daily; adjust as needed. Maximum: 32 mg/day.
1.34 mg orally twice daily; maximum 8.04 mg/day.
None Documented
None Documented
10-12 hours terminal elimination half-life; steady-state reached in 2-3 days
Terminal half-life 12–15 hours; clinical dosing interval every 12 hours.
Renal (40-50% as metabolites, <5% unchanged); biliary/fecal (minor, ~10-20%)
Primarily renal: ~60% unchanged; biliary/fecal: ~30% as metabolites; minor via feces.
Category C
Category C
Antihistamine
Antihistamine